NDAQ Nasdaq Inc.

Annual Changes to the Nasdaq Biotechnology Index

Annual Changes to the Nasdaq Biotechnology Index

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 100 securities will be added to the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqABUSArbutus Biopharma Corporation
NasdaqADAPAdaptimmune Therapeutics plc
NasdaqAKUSAkouos, Inc.
NasdaqALTAltimmune, Inc.
NasdaqALVRAlloVir, Inc.
NasdaqALXOALX Oncology Holdings Inc.
NasdaqAMTIApplied Molecular Transport Inc.
NasdaqANNXAnnexon, Inc.
NasdaqAPLTApplied Therapeutics, Inc.
NasdaqAPREAprea Therapeutics, Inc.
NasdaqARCTArcturus Therapeutics Holdings Inc.
NasdaqARQTArcutis Biotherapeutics, Inc.
NasdaqAVDLAvadel Pharmaceuticals plc
NasdaqAZNAstraZeneca PLC
NasdaqBDTXBlack Diamond Therapeutics, Inc.
NasdaqBEAMBeam Therapeutics Inc.
NasdaqBNTXBioNTech SE
NasdaqCABACabaletta Bio, Inc.
NasdaqCALACalithera Biosciences, Inc.
NasdaqCDXSCodexis, Inc.
NasdaqCLVSClovis Oncology, Inc.
NasdaqCNCEConcert Pharmaceuticals, Inc.
NasdaqCNSTConstellation Pharmaceuticals, Inc.
NasdaqCRNXCrinetics Pharmaceuticals, Inc.
NasdaqCRTXCortexyme, Inc.
NasdaqFMTXForma Therapeutics Holdings, Inc.
NasdaqFPRXFive Prime Therapeutics, Inc.
NasdaqFREQFrequency Therapeutics, Inc.
NasdaqFULCFulcrum Therapeutics, Inc.
NasdaqFUSNFusion Pharmaceuticals Inc.
NasdaqGBIOGeneration Bio Co.
NasdaqGMDAGamida Cell Ltd.
NasdaqHARPHarpoon Therapeutics, Inc.
NasdaqIDYAIDEAYA Biosciences, Inc.
NasdaqIGMSIGM Biosciences, Inc.
NasdaqIMABI-MAB
NasdaqIMUXImmunic, Inc.
NasdaqIMVTImmunovant, Inc.
NasdaqINZYInozyme Pharma, Inc.
NasdaqISEEIVERIC bio, Inc.
NasdaqITOSiTeos Therapeutics, Inc.
NasdaqJNCEJounce Therapeutics, Inc.
NasdaqKALAKala Pharmaceuticals, Inc.
NasdaqKALVKalVista Pharmaceuticals, Inc.
NasdaqKDMNKadmon Holdings, Inc.
NasdaqKDNYChinook Therapeutics, Inc.
NasdaqKLDOKaleido Biosciences, Inc.
NasdaqKMDAKamada Ltd.
NasdaqKNSAKiniksa Pharmaceuticals, Ltd.
NasdaqKROSKeros Therapeutics, Inc.
NasdaqKRYSKrystal Biotech, Inc.
NasdaqKZRKezar Life Sciences, Inc.
NasdaqLEGNLegend Biotech Corporation
NasdaqLRMRLarimar Therapeutics, Inc.
NasdaqMDGLMadrigal Pharmaceuticals, Inc.
NasdaqMNOVMediciNova, Inc.
NasdaqMRNSMarinus Pharmaceuticals, Inc.
NasdaqMRSNMersana Therapeutics, Inc.
NasdaqNKNantKwest, Inc.
NasdaqNKTXNkarta, Inc.
NasdaqNLTXNeoleukin Therapeutics, Inc.
NasdaqNRIXNurix Therapeutics, Inc.
NasdaqNVAXNovavax, Inc.
NasdaqNXTCNextCure, Inc.
NasdaqOCULOcular Therapeutix, Inc.
NasdaqODTOdonate Therapeutics, Inc.
NasdaqORICOric Pharmaceuticals, Inc.
NasdaqOVIDOvid Therapeutics Inc.
NasdaqPAHCPhibro Animal Health Corporation
NasdaqPANDPandion Therapeutics Inc.
NasdaqPASGPassage Bio, Inc.
NasdaqPCVXVaxcyte, Inc.
NasdaqPLRXPliant Therapeutics, Inc.
NasdaqPRTKParatek Pharmaceuticals, Inc.
NasdaqPRVBProvention Bio, Inc.
NasdaqPSTXPoseida Therapeutics, Inc.
NasdaqRAPTRAPT Therapeutics, Inc.
NasdaqRDHLRedhill Biopharma Ltd.
NasdaqREPLReplimune Group, Inc.
NasdaqRLAYRelay Therapeutics, Inc.
NasdaqRLMDRelmada Therapeutics, Inc.
NasdaqRNAAvidity Biosciences, Inc.
NasdaqRPRXRoyalty Pharma plc
NasdaqRPTXRepare Therapeutics Inc.
NasdaqRVMDRevolution Medicines, Inc.
NasdaqSELBSelecta Biosciences, Inc.
NasdaqSMMTSummit Therapeutics Inc.
NasdaqSNDXSyndax Pharmaceuticals, Inc.
NasdaqSPROSpero Therapeutics, Inc.
NasdaqSTROSutro Biopharma, Inc.
NasdaqSURFSurface Oncology, Inc.
NasdaqSWTXSpringWorks Therapeutics, Inc.
NasdaqTCRRTCR2 Therapeutics Inc.
NasdaqVIEViela Bio, Inc.
NasdaqVIRVir Biotechnology, Inc.
NasdaqVSTMVerastem, Inc.
NasdaqVYNEVYNE Therapeutics Inc.
NasdaqXENEXenon Pharmaceuticals Inc.
NasdaqZIOPZIOPHARM Oncology Inc
NasdaqZNTLZentalis Pharmaceuticals, Inc.

As a result of the reconstitution, the following 16 securities will be removed from the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqADMAADMA Biologics Inc
NasdaqAMRSAmyris, Inc.
NasdaqAXNXAxonics Modulation Technologies, Inc.
NasdaqCERSCerus Corporation
NasdaqCRBPCorbus Pharmaceuticals Holdings, Inc.
NasdaqEOLSEvolus, Inc.
NasdaqEYPTEyePoint Pharmaceuticals, Inc.
NasdaqGLYCGlycoMimetics, Inc.
NasdaqGRTSGritstone Oncology, Inc.
NasdaqLXRXLexicon Pharmaceuticals, Inc.
NasdaqNVCRNovoCure Limited
NasdaqOPTNOptiNose, Inc.
NasdaqPRQRProQR Therapeutics N.V.
NasdaqQTRXQuanterix Corporation
NasdaqSLDBSolid Biosciences Inc.
NasdaqTECHBio-Techne Corp

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on , on Twitter , or at .

Media Relations Contact

Emily Pan

(646) 637-3964

Issuer & Investor Contact

Index Client Services

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG-



EN
12/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nasdaq Inc.

 PRESS RELEASE

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Sto...

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date October 15, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of October 15, 2025, short interest in 3,382 Nasdaq Global MarketSM securities totaled 13,834,913,159 shares compared with 14,078,324,727 shares in 3,366 Global Market issues reported for the prior settlement date of September 30, 2025. The mid-October short interest represents 2.09 days compared with 2.16 days for the prior reporting period. Short interest in 1,682 securities on The Nasdaq Capital M...

 PRESS RELEASE

Nasdaq Halts Empro Group Inc.

Nasdaq Halts Empro Group Inc. NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Empro Group Inc. (Nasdaq: EMPG) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in EMPG from 04:00:00 on October 9, 2025 to 23:59:00 on October 22, 2025. The last sale price of the company’s ordinary shares was $17.36.  More information about the SEC’s order can be found at . Trading will remain halted until Empro Group Inc. has fully satisfied Nasdaq’s...

 PRESS RELEASE

Nasdaq Halts NusaTrip Incorporated

Nasdaq Halts NusaTrip Incorporated NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in NusaTrip Incorporated (Nasdaq: NUTR) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in NUTR from 04:00:00 on October 9, 2025 to 23:59:00 on October 22, 2025. The last sale price of the company’s ordinary shares was $9.00.  More information about the SEC’s order can be found at . Trading will remain halted until NusaTrip Incorporated has fully sati...

 PRESS RELEASE

Nasdaq Announces Quarterly Dividend of $0.27 Per Share

Nasdaq Announces Quarterly Dividend of $0.27 Per Share NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on December 19, 2025 to shareholders of record at the close of business on December 5, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology co...

 PRESS RELEASE

Nasdaq Reports Third Quarter 2025 Results; Surpassing $1 Billion in So...

Nasdaq Reports Third Quarter 2025 Results; Surpassing $1 Billion in Solutions Quarterly Revenue and $3 Billion in ARR NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the third quarter of 2025. Third quarter 2025 net revenue1 was $1.3 billion, an increase of 15% over the third quarter of 2024, or up 11% on an organic2 basis. This included Solutions3 revenue growing 15%, or up 10% on an organic basis.Annualized Recurring Revenue (ARR)4 of $3.0 billion increased 10% over the third quarter of 2024, or up 9% on an organic basis. Ann...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch